- Home
- SABR vs MLYS Comparison
SABR vs MLYS Comparison
Compare SABR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- MLYS
- Stock Information
- Founded
- SABR 2006
- MLYS 2019
- Country
- SABR United States
- MLYS United States
- Employees
- SABR N/A
- MLYS N/A
- Industry
- SABR Computer Software: Programming Data Processing
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- MLYS Health Care
- Exchange
- SABR Nasdaq
- MLYS Nasdaq
- Market Cap
- SABR 981.2M
- MLYS 1.0B
- IPO Year
- SABR 2014
- MLYS 2023
- Fundamental
- Price
- SABR $2.52
- MLYS $15.58
- Analyst Decision
- SABR Hold
- MLYS Strong Buy
- Analyst Count
- SABR 4
- MLYS 3
- Target Price
- SABR $4.15
- MLYS $33.00
- AVG Volume (30 Days)
- SABR 6.2M
- MLYS 866.7K
- Earning Date
- SABR 05-07-2025
- MLYS 05-12-2025
- Dividend Yield
- SABR N/A
- MLYS N/A
- EPS Growth
- SABR N/A
- MLYS N/A
- EPS
- SABR N/A
- MLYS N/A
- Revenue
- SABR $3,023,296,000.00
- MLYS N/A
- Revenue This Year
- SABR $6.71
- MLYS N/A
- Revenue Next Year
- SABR $5.20
- MLYS N/A
- P/E Ratio
- SABR N/A
- MLYS N/A
- Revenue Growth
- SABR 2.56
- MLYS N/A
- 52 Week Low
- SABR $1.93
- MLYS $8.24
- 52 Week High
- SABR $4.63
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SABR 44.89
- MLYS 54.41
- Support Level
- SABR $2.44
- MLYS $15.45
- Resistance Level
- SABR $2.69
- MLYS $16.11
- Average True Range (ATR)
- SABR 0.12
- MLYS 0.96
- MACD
- SABR -0.02
- MLYS -0.05
- Stochastic Oscillator
- SABR 12.50
- MLYS 51.56
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.